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ABSTRACT
Sirolimus (SRL) is a potent immunosuppressant. Therapeutic drug monitoring (TDM) of SRL is required to optimize the therapy.
Immunoassay, high-performance liquid chromatography with ultraviolet detection (HPLC-UV), and HPLC with mass-spectrometric
detection (HPLC-MS or HPLC/MS/MS) have been used in the analysis of SRL. The purpose of this study was to share our experience
in validating a HPLC-UV method for analyzing SRL and to have an overview of HPLC-UV methods used in SRL assay. A validated
HPLC/UV method developed by Wyeth-Ayerst Research with minor modification was use to determine SRL concentration in human
whole blood. An Alltima C18 column (5 µm, 150 × 2.1 mm) was used as the stationary phase. The mobile phase was 60% acetonitrile in water, and the flow rate was 0.5 mL/min. Samples were prepared by spiking human whole blood (0.5 mL) with the internal
standard (IS) and designated amount of SRL, except blank. Zinc sulfate (50 g/L, 1 mL) and acetone (1 mL) were used for hemolysis
and deproteinization. After alkalizing supernatant with 100 mM NaOH (0.2 or 0.3 mL), 1-chlorobutane (2 mL) was used for extraction. The 1-chlorobutane layer was dried, reconstituted with mobile phase and back extracted with 0.5 mL of n-hexane. The limitation
of quantification was 2.5 ng/mL and the standard curve was linear at the concentration range of 2.5-75 ng/mL. The intraday and
interday coefficients of variation were 2.1-5.2% and 2.8-5.7%, respectively. The intraday and interday relative errors were -0.03-5.3%
and 0.7-3.3%, respectively. The recoveries for SRL and the IS were 78.5-92.8% and 76.9 ± 3.9 %, respectively. The samples were
proven to be stable after 3 freeze/thaw cycles, and the extract was stable over 24 hr at an autosampler set to 4˚C. In addition to an
overview of the chemical properties of SRL, different HPLC-UV methods for the quantification of SRL were provided to identify
analytic parameters that are critical for the establishment of HPLC-UV assay for SRL.
Key words: immunosuppressive, high-performance liquid chromatography, sirolimus, therapeutic drug monitoring, transplantation

INTRODUCTION
Sirolimus (Rapamycin, AY-22989, Wy-090217, SRL),
a lactone-lactam macrolide antibiotic derived from
Streptomyces hygroscopicus(1), is a potent immunosuppressive agent that was approved by the U.S. Food and Drug
Administration (FDA) for use with cyclosporine- or
tacrolimus-based immunosuppression in kidney transplantation(2,3). In addition, the European regulatory authorities
have approved the drug for use in combination with corticosteroids in kidney transplantation(3). SRL has not only
a considerable inter- and intra-individual variability (about
8 folds) in clearance, but also sub-optimal correlations
between blood concentrations and dose or demographic
features(4). Fortunately, the excellent correlation between
steady-state trough concentration (C0) and area under the
concentration-time curve (AUC) makes C0 a simple and
reliable index of SRL exposure(5). The target ranges of
SRL C0 start at 5 ng/mL(3). A clear relationship exists
* Author for correspondence. Tel: +886-2-23123456 ext. 8394;
Fax: +886-2-23938231; E-mail: shaowen@ha.mc.ntu.edu.tw,
flwu@ha.mc.ntu.edu.tw

between C 0 of SRL and efficacy and toxicity (5) .
Therapeutic drug monitoring (TDM) of SRL is important to
optimize its therapeutic effects(6,7). Several types of analytical methods have been used in TDM of SRL, including
immunoassay, high-performance liquid chromatography
with ultraviolet detection (HPLC-UV), and HPLC with
mass-spectrometric detection (HPLC-MS or HPLC/MS/
MS)(8). For the phase III clinical trials, an investigational
microparticulate enzyme-linked immunoassay (MEIA,
Abbott Laboratories, Abbott Park, Illinois) was used (9,10).
The quantification limits were 3.0–22 ng/mL, not interfered
by cyclosporine (CsA), tacrolimus (FK) or mycophenolate
mofetil (9,10) . A positive mean bias of 41.9% when
compared with HPLC-MS is potentially attributable to the
interference of SRL metabolites(9). However, for reasons
unrelated to its technical performance, the kit was not commercially available(3). HPLC-UV and HPLC/MS/MS spectroscopy are the methods of choice for determination of
whole-blood SRL(11). The former method has a sensitivity
and lower limits of quantification (LOQ) of < 1 ng/mL,
while the latter have sensitivities of 0.4-6.5 ng/mL and
LOQ of 1-6.5 ng/mL(11-18). Although HPLC-UV methods
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use a less sophisticated mode of detection than HPLC-MS
or HPLC/MS/MS methods and are complicated by interfering peaks in the chromatograms, these two HPLC methods
provide similar results(8). In addition, HPLC-UV is more
readily available in clinical and reference laboratories. As
the absorption peak of SRL is relatively small, chromatographic interference from temperature, test tubes, biologic
matrices and chemical solvent make assay of SRL by
HPLC-UV a challenge to many laboratories. The goal of
this study was to share our experience in validating an
HPLC-UV method for analyzing SRL, as well as to give an
overview of HPLC-UV methods used in SRL assay.

MATERIALS AND METHODS
A validated method developed by Wyeth-Ayerst
Research (Princeton, NJ)(18) with minor modification was
used in our lab. The validation was performed in accordance with the regulatory guidelines of the U.S. FDA(19).
I. Reagents and Chemicals
SRL was obtained form Wyeth-Ayerst Analytical R &
D (Pearl River, NY). The internal standard (IS, 32desmethoxy rapamycin) was obtained from Wyeth-Ayerst
Research (Princeton, NJ). HPLC grade solvents, such as
methanol (MeOH), acetone, 1-chlorbutane (C4H9Cl) and
acetonitrile (CH3CN), were purchased from Merck KgaA
(Darmatadt, Germany). n-hexane (HPLC grade) and
sodium hydroxide (NaOH) 50% solution were purchased
from Mallinckrodt Baker. Inc. (Phillipsburg, NJ, USA).
Pure water was prepared by Millipore Direct-QTM. Zinc
sulfate heptahydrate (GR reagent, 99.5% minimum purity)
was purchased from RdH Laborchemikalien GmbH & Co.
KG. (Seelze, Germany).
II. Equipment
Vortex mixer (Thermolyne, MAXI-MIX II, Dubuque,
Iowa, USA) and large capacity vortexer (Glas-Col, 099ALC1012, Indiana, USA), sonicator (Elma-Hans
Schmidbauer GmbH & Co KG, T710DH, Singen,
Germany), centrifuge (Kubota Corporation, KN-70, Osaka,
Japan) and nitrogen gas blower/dry thermo bath (Eyela,
MGS-1000, Tokyo, Japan) were used during the extraction
procedure. A HPLC system (Agilent Technologies Inc.,
1100 LC, Palo Alto, California) consisted of a pump
(G1311A ), degasser (G1322A), photodiode array (PDA)detector (G1315B), autosampler (G1329A), autosampler
temperature controller (G1330A) and thermostat column
compartment (G1316A) was used to analyze the samples.
III. Preparation of Calibrator and Quality Control (QC)
Samples
All the stock or spiking solutions were prepared in

glass volumetric flasks, then transferred to glass or
polypropylene (PP) tubes, and stored at -80˚C when not in
use. Stock standard of SRL (100 µg/mL) was prepared in
MeOH. The IS spiking solution was prepared at a concentration of 250 ng/mL in 50% methanol water.
Calibrators and quality-control (QC) samples were
prepared in potassium EDTA human whole blood
(Biological Specialty Corporation, Colmar, PA, USA) using
stock standard solutions. Calibration curves contained
seven non-zero calibrators assayed in duplicate (nominal
SRL concentrations: 2.5, 5, 10, 15, 25, 50 and 75 ng/mL).
The correlation coefficient (r) between concentration and
the peak height ratio should be ≥ 0.98. Recalculated calibration data should be within ± 20% of the nominal value.
A maximum of two calibration standards (at the different
concentrations) might be removed as outliers.
IV. Extraction Procedure
The whole blood sample (0.5 mL) was transferred to a
16 × 100 mm screw-cap (Teflon lined cap, Corning Inc.,
Corning, NY, USA) glass culture tubes, spiked with
75 µL of IS, and vortex-mixed for 1 min. One milliliter of
Zinc sulfate (50 g/L) and 1 mL of acetone were added to
each tube. The tubes were capped, vortex-mixed for 1 min,
and centrifuged at 3000 rpm and ambient temperature for 7
min. The supernatant was poured off into a 16 × 100 screw
cap tube. NaOH (200 µL or 300 µL, 100 mM) was added
to each tube and vortex-mixed briefly. 1-chlorobutane (2
mL) was added to each tube. The tubes were capped,
vortex-mixed for 1min, and centrifuged at 3000 rpm and
ambient temperature for 7 min. The upper organic layer
was transferred to a 10 mL conical screw cap centrifuge
tube (Kimble Glass Inc., Vineland, NJ, USA), and then
dried under nitrogen at ambient temperature for approximately 30 min. The dried extracts were reconstituted with
150 µ L of mobile phase, capped and vortex-mixed for
approximately 20 sec. n-hexane (500 µL) was added to
each tube for back-extraction. The tubes were capped with
Teflon-lined caps, vortex-mixed for approximately 30 sec,
and centrifuged for 3 min at 3000 rpm and ambient temperature. After removing and discarding the upper hexane
layer from each sample, the extracts were dried under
nitrogen at ambient temperature for 1 min to remove last
traces of hexane. The extracts were transferred to 250 µL
conical glass inserts in 1.5 mL autosampler amber glass
sample vials. The vials were capped with screwpolypropylene cap with Teflon/silicone rubber septa (Sun
International, Wilmington, NC, USA) and placed on the
HPLC autosampler.
V. HPLC Analysis
The analytical column was Alltima C18 column (150
× 2.1 mm, particle size 5 µm from Alltech Associates, Inc.
USA) with Alltima C18 column guard column (7.5 × 2.1
mm, particle size 5 µ m from Alltech Associates, Inc.
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USA). The autosampler had temperature controller (set to
4˚C) and equipped with column oven set at 50˚C. The
mobile phase was a mixture of CH3CN 60% in H2O, and
injection volume was 50 µ L. The flow rate was 0.5
mL/min which led to a typical pressure of 90-120 bars
(1305-1740 psi). SRL and the IS were detected by UV
absorption at 278 nm at retention time of approximately 9
and 11 min.
Measured (or calculated) SRL concentrations (ng/mL)
were obtained from the weighted linear regression line
relating to the peak height ratios of SRL/IS (Y) to the concentration ratios of SRL/IS (X), with weight = 1/(SRL
concentration).

injections. Six measurements were made at each concentration immediately after extraction and after storage in
autosampler (set to 4˚C) for 24 hr.
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Figure 1. Typical chromatograms of (A) drug-free whole blood, (B)
extract of blank whole blood spiked with 2.5 ng/mL SRL and 32.6
ng/mL IS, (C) extract of blank whole blood spiked with 75 ng/mL
SRL and 32.6 ng/mL IS and (D) extract of blood from a patient
receiving SRL (4.45 ng/mL).
Both SRL and IS have two peaks (isomer B and isomer C). Peak of
SRL isomer C can be clearly identified only at high concentration as
in (C).
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Table 1. Precision and accuracy in determining of SRL concentrations in human whole blood and limits of quantification (N = 6)
Intraday
Interday
Sample (ng/mL)
Mean ± SD
CV (%)
Accuracy (%)
Mean ± SD
CV (%)
Accuracy (%)
LLOQ (2.5)
2.2 ± 0.1
6.0
88.7
Calibrator (5)
4.7 ± 0.4
9.4
94.3
Low QC (7.5)
7.9 ± 0.4
4.6
105.3
7.7 ± 0.4
4.6
103.3
Mid QC (22.5)
22.5 ± 1.2
5.2
100.0
22.7 ± 1.3
5.7
100.7
High QC (58)
58.0 ± 1.2
2.1
100.0
58.9 ± 1.6
2.8
101.5
ULOQ (75)
68.6 ± 2.1
3.0
91.5
LLOQ: lower limit of quantification; QC: quality control; ULOQ: upper limit of quantification.

Table 2. Recovery and stability of sample extracts (N = 6)
Nominal concentration
Recovery (%)
(ng/mL)
SRLa
ISb
7.5
89.1 ± 6.3
22.5
84.8 ± 6.4
58.0
82.5 ± 3.2
32.6
76.9 ± 3.9
a
b
SRL: sirolimus.
IS: internal standard.

Table 3. Sample stability after freeze/thaw cycles (N = 6)
Nominal concentration
(ng/mL)
Immediately after preparation
15.0
1st freeze/thaw cycle
15.0
2nd freeze/thaw cycle
15.0
3rd freeze/thaw cycle
15.0

RESULTS
I. Specificity

Stability of sample extracts (relative error, %)
Immediately after extraction
24 hr after extraction
-0.8
3.0
0.4
3.6
0.9
4.7

Mean ± SD (ng/mL)
15.21 ± 0.81
15.03 ± 0.28
13.39 ± 0.69
15.62 ± 1.85

Measured concentration
CV (%)
Relative error (%)
5.3
1.4
1.8
0.2
5.1
-10.7
11.8
4.1

(CV) and relative errors were 2.1-5.2% and -0.03-5.3%,
respectively. Interday imprecision and relative errors were
2.8-5.7% and 0.7-3.3%, respectively (Table 1).

The specificity of the method was demonstrated by the
absence of interfering chromatographic peaks with retention
times equal to those of SRL or IS in the extracts of blank
human whole-blood samples. Representative chromatograms for extracts from a blank human whole blood
sample, the lowest (2.5 ng/mL) and highest (75 ng/mL) calibrators, and a sample from a patient receiving SRL (4.45
ng/mL) are presented in Figure 1 (A), (B), (C) and (D),
respectively. The retention time occasionally varied by 1
min or so after changing the column or solvent, but
remained stable during the same run. Both SRL and IS
have two peaks (isomer B and isomer C). Because isomer
B is the main isomer, we use only the peak of isomer B for
calculation. Isomer C, on the other hand, is a minority in
various SRL formulations and its peak can be clearly identified only at high concentration.

III. Recovery and Stability of Sample Extracts

II. Accuracy, Precision and Limit of Quantification

The measured values immediately after preparation
and after freeze/thaw cycle (s) were all within ± 15.0% of
the expected value. The relative error of mean measured
value immediately after preparation was 1.4%. Reanalysis
after the first, second and third freeze/thaw cycle showed
corresponding relative errors of 0.2%, -11.6% and 4.1%,
respectively (Table 3). All the CVs were less than 12%.

The CV and relative error values for the LLOQ were
6.0% and 11.3%, respectively, while those for ULOQ were
3.0% and 8.5%, respectively (Table 1). The precision is
3.0-9.4%. The correlation between concentration ratio and
the peak height ratio were > 0.998. Intraday imprecision

The recovery of SRL from human whole blood ranged
from 78.5% to 92.8%, and 76.9 ± 3.8% for the IS (Table 2),
respectively.
The measured values immediately after extraction and
more than 24 hr after extraction were within ±7.2% and
±10.9% of the expected value, respectively. The relative
errors of mean measured values of the low, medium and
high QC level immediately after extraction were -0.8%,
0.4%, 0.9%, respectively. Reanalysis of QC sample
extracts after placing in autosampler for more than 24 hr
showed corresponding relative errors of 3.0%, 3.6%, 4.7%,
respectively (Table 2).
IV. Sample Stability

1-50 ng/mL

1-250 ng/mL

Yatscoff et al. (1992)
1 ng/mL if 2 mL of
blood used
0.5 ng/mL if 1 mL of
blood used

12. back extraction

8. layer used
9. water bath
10. evaporate to dryness
11. reconstitute solvent
of dried extract

7. dry ice bath

tBME
40˚C
N2 gas
EtOH 150 µL × 2,
dried then mobile
phase 100 µL

3000 g × 5 min at
autosampler vial

1600 g × 5 min

C6H14 0.1 mL

N2 gas
Mobile phase 100 µL

(C2H5)2O

30 sec

6. centrifugation

4. vortex time

2 mL
200 ng/mL 50 µL
13.3 g/L K2CO3 3 mL,
(C2H5)2O 5.5 mL

Single extraction with
back extraction

10 min

2 extractions

Liquid/liquid extraction

No

15 min

No

Precipitation
Vortex mixed
Centrifuge

-40˚C

5. shaking time

-40˚C, dark

Storage of stock standards

8 µg/mL in 95% EtOH/
H2O

0.25-1 mL
0.1 mg/mL 20 µL
0.01 M Na2CO3 0.25-1 mL
(= blood volume)
tBME 7 mL × 2
MeOH 25-100 µL
20 sec

0.1 mg/mL in MeOH

Stock standards of IS

4 µg/mL in 95%
EtOH/H2O

1. blood
2. IS
3. extraction solvent

0.5 mg/mL in MeOH

Stock standards of SRL

β-Estradiol-3-methyl ether Demethyl-RAPA
(DMRAP)

Assay range

Internal standard (IS)

Napoli et al. (1994, 1996)
1 ng/mL

References
Lower detection limit
(LOD)

Table 4. Comparison of HPLC-UV methods used in SRL assay(12-18)

High speed 1 min,
sonicated × 5 min
1 hr on a reciprocal shaker
at 250 shakes/min
2000 g (3000 rpm) × 10 min,
refrigerated centrifuge
Upright, dry ice/methanol
bath × 5 min to form
a semi-frozen pellet
C4H9Cl
45˚C
N2 gas
70% MeOH/ H2O, v/v

1 mL
2.5 µg/mL 50 µL
0.1M CH3COONa
buffer (pH 4.7) 3mL
C4H9Cl 7 mL

Single extraction

No

100 µg/mL in MeOH,
dilute with water to
2.5 µg/mL

250 µg/mL in MeOH,
dilute with H2O to 2
substock: 25 µg/mL,
0.25 µg/mL

32-Desmethoxy RAPA

2.5-150 ng/mL

Maleki et al. (2000)
2.5 ng/mL

C6H14 0.5 mL

C4H9Cl
Ambient temperature
N2 gas
Mobile phase 150 µL

3000 rpm × 5 min

No

1 min

0.5 mL
250 ng/mL 75 µL
0.1 M NaOH 0.2 mL,
1- C4H9Cl 2 mL

Single extraction with
back extraction

C6H14 0.5 mL

tBME/C4H9Cl/MeOH
60˚C
N2 gas
50% CH3CN/H2O,
0.5 mL, v/v

1500 g × 10 min

No

100 rpm × 20 min

1 mL
100 µL
tBME/ C4H9Cl/MeOH,
45/45/10, 4 mL

Single extraction with
back extraction

C4H9Cl/(C2H5)2O
~40˚C
N2 gas
60% MeOH/ H2O,
1 mL, v/v

Reciprocal shaking
30 min
5000 g × 10 min

1 mL
400 ng/mL 50 µL
0.1 M CH3COONa
buffer (pH 4.7) 1 mL;
C4H9Cl /(C2H5)2O,
50/50, 7mL

Single extraction

No

5% ZnSO4 1mL, acetone1 mL
20 sec
3000 rpm, 5min

400 ng/mL in MeOH

200 µg/mL in MeOH

32-Desmethoxy RAPA

1-50 ng/mL

Svensson et al. (1997)
0.4 ng/mL

-40˚C
No

32-Desmethoxy RAPA

6.5-250 ng/mL

Holt et al. (2000)
6.5 ng/mL

-80˚C

1 mg/mL in MeOH, dilute
with 50% MeOH/H2O
to intermediate stock:
100 µg/mL, 2.5 µg/mL

1 mg/mL in MeOH,
dilute with 50%
MeOH/H2O to
substock: 100 µg/mL

32-Desmethoxy RAPA

2.5-75 ng/mL

French et al. (2001)
2.5 ng/mL if 0.5 mL of
blood used
1.25 ng/mL if 1 mL of
blood used
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No

THF 1mL at 30 min
via a 2-position actuator

~20-21 min

Elution time of SRL

Flush solution

Elution time of IS

278 nm

-21-27%

-9-14%

-9-4%

Relative error
(within-day)

Relative error
(between-day)

9.8-14.4%

9.8-15.4%

1.9-8.1%

Method of SRL
concentration
determination

6-17%

70%

SRL/IS peak-height
ratio

Recovery of IS

CV (between-day)

~100%

CV (within-day)

35.3% ± 4.94%

96%

Relative recovery

0.35 mL/min

Absolute recovery

Recovery of SRL

<40 min

~18-19 min

Elution time

276 nm

1 mL/min

85% MeOH/ H2O, v/v

Column temperature

Mobile phase

Flow rate

70% MeOH/H2O, v/v

40˚C

Column

UV detection

2 Suplecosil reverse-phase 2 Spherisorb tandem
tandem C18 column
C18 column
(5 µm, 25 × 0.21 cm)
(5 µm, 25 × 0.46 cm)
45˚C

Upchurch 0.5 µm

Precolumn filter (guard
column, column saver)

4.2-5.7%

-0.2~ -4.8%

2.6-13.0%

12.0-14.4%

SRL/IS peak-height
ratio

80.0-88.8%

88-106.3%

18 min

100% CH3CN

16 min

35 min

1 mL/min

278 nm

MeOH/CH3CN/H2O
(68/2/30)

60 ± 2˚C

(3 µm, 15 × 0.46 cm)

1 C18 analytical column

C18 guard column
& a column saver

130 µL

85 µL

Sample for each analysis

No
4 ± 2˚C

70 µL

No

Yatscoff et al. (1992)
Maleki et al. (2000)
30 sec
3000 rpm × 5 min
Mobile phase (lower layer) Supernatant

Autosampler temperature 22˚C

Chromatography

Supernatant

Solid phase extraction

Napoli et al. (1994, 1996)

References
13. vortex time
14. centrifuge
15. layer for analysis

Table 4. Comparison of HPLC-UV methods used in SRL assay(12-18)

1.1-5.2%

-3.7%-7.5%

2.5-6.9%

0.9-8.5%

SRL/IS peak-height
ratio

81.8%

~100%

80.6%

13 min

10.4 min

20 min

0.5 mL/min

278 nm

H3CN/H2O (60/40)

50˚C

1 Alltima C18,
analytical column
(5 µm, 15 × 0.21 cm)

C18 guard column

50 µL

4˚C

No

French et al. (2001)
30 sec
2600 g × 2 min
Mobile phase (lower layer)

-9.7%-9.2%

0.4- 6.6%

3.1-5%

Peak-area ratio
of in-house
control/analytes

62.7 ± 3.6%

81.5 ± 4.3%

28 min

~22 min

1.5 mL/min

278 nm

65% CH3CN/H2O, v/v

50˚C

Ultrsphere C18-bonded
silica column
(5 µm, 25 × 0.46 cm)

200 µL

No

Holt et al. (2000)
100 rpm × 10 min
1500 g × 10 min
Lower layer

9.8% at 5 ng/mL
5.6% at 40 ng/mL

~45%

~45%

~10 min

0.3 mL/min

278 nm

MeOH/CH3CN/ H2O
(34/38/28)

70˚C

Shandon Hypersil
BDS C18 column
(3 µm, 10 × 0.3 cm)

50 µL

Yes

–

Svensson et al. (1997)
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SRL 0, 6.5, 13, 25.9,
51.8, 103.7, 207.4,
356.4 ng/mL

~22˚C, 54 hr
-80˚C

Definitive therapeutic levels of SRL remain to be
established. Target C 0 depends on the concomitant
immunosuppressive regimen and post-transplant interval.
There are no conclusions on the most appropriate blood
levels of calcineurin inhibitors (CNIs) and SRL when used
in combination. A SRL level of 6-12 ng/mL is considered
appropriated when combined with tacrolimus (FK)(20). If
cyclosporine (CsA) is being used at C0 of 75-150 ng/mL, a
SRL C 0 of 5-15 ng/mL is considered appropriate (4) .
Increased hematological toxicity and hyperlipidemia in
human were observed when SRL C0 exceeded 15 ng/mL(7).
In 1995, consensus guidelines for TDM of SRL were
developed(11). Much has changed since the original consensus document(3). Whole-blood trough levels are indicated
for TDM(3,7,11,21). The recommended time for collection is
within 1 hr prior to the next oral dose(11). For multiple daily
dosing, collection should be made at the same time during
the day to ensure intrapatient consistency(11). The frequency
of monitoring of SRL is lower than CNI due to its long halflife(3,22). A new steady state can be achieved one week or
longer after dosage initiation or adjustment.
Measurement of SRL blood concentration is not a
requirement of the U.S. FDA, but Europe health authorities(3). TDM is recommended for pediatric patients and
those with hepatic impairment even when fixed-dose
regimen is used. In SRL-based regimen or concentrationguided dosing, routine TDM of SRL is needed(3). TDM is
also recommended when potent inducers or inhibitors of
CYP3A4 are co-administered, or when dose of concurrent
cyclosporine is markedly reduced or discontinued(3,11).

Yatscoff et al. (1992)
2.0

SRL 0, 2.5, 5, 10, 25,
50, 75, 100, 150 ng/mL

SRL 0, 2.5, 5, 10, 15,
25, 50, 70, 75 ng/mL

I. Guidelines for TDM of SRL

SRL 0, 2, 5, 10, 20,
30, 40, 50 ng/mL

4˚C overnight

Calibration curve

Storage of sample
extract

EtOH: ethanol.
(C2H5)2O: diethyl ether.
CH3CN: acetonitrile.
CH3COONa: sodium acetate.
C4H9Cl: 1-chlorobutane (=butyl chloride).
C6H14: hexane.
H2O: deionized water.
MeOH: methanol.
RPAP: sirolimus.
SRL: sirolimus.
tBME: t-butyl methyl ether.
ZnSO4: zinc sulfate.

Napoli et al. (1994, 1996)
3.0 = 0.4 ng SRL

II. Chemical Properties and Sample Collection of SRL

References
Signal to a noise ratio

Table 4. Comparison of HPLC-UV methods used in SRL assay(12-18)

Maleki et al. (2000)

French et al. (2001)

Holt et al. (2000)

Svensson et al. (1997)

DISCUSSION

SRL is a white to off-white powder, insoluble in water;
very slightly soluble in hexane and petroleum ether; soluble
in methanol, diethyl ether, and N, N-dimethylformamide
(DMF); and freely soluble in benzyl alcohol, chloroform,
acetone, and CH3CN(23,24). As 95% of SRL is partitioned
into red blood cells, whole blood is the established biologic
matrix for routine TDM(3). Human whole-blood samples
should be collected in potassium ethylenediamine-tetraacetate (EDTA) containing blood-collection tubes and
protected from light by wrapping in foil or brown plastic
bag(25). Samples collected in this fashion are stable for up
to one week at 2-8˚C, and up to 3 months at -20˚C. For
prolonged storage of specimens, -70˚C or -80˚C is recommended. Although stability of SRL in blood samples has
been shown at temperatures up to 30˚C(26), SRL in blood
samples is unstable at temperatures above 35˚C(27).
III. HPLC-UV Assays for SRL
Assay of SRL by HPLC-UV is a challenge to many
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laboratories(27-29). Several validated HPLC-UV assays
have been reported for determining SRL concentration in
whole blood (Table 4) (12-18) . The absolute analytic
recovery of an HPLC method used to measure SRL should
be >60% with the analytic recovery relative to an IS in the
range of 90-110%(11). The absolute recovery rates reported
by Yatscoff et al.(15) and Svensson et al.(12) were not satisfactory, whereas their relative recoveries met the requirement (Table 4). Results for a new procedure should be
compared with a validated one for at least 30 specimens of
blood per transplant type or 100 in total. Standard statistical evaluation of the linear-regression data should be
studied, including slope and standard deviation (SD) of the
slope, y-intercept, SD of the intercept, and SD of the
estimate (Sy/x, standard error (SE) of the regression). t-test
should be performed on the slope and the intercept to
demonstrate that they are not statistically different from 1.0
or 0.0, respectively at the CI95%. Slope should differ by
<10% from the line of identity (slope 1.0: acceptable 0.91.1), the y-intercept, and the Sy/x by no more than 5 ng/mL
(11)
. Proficiency test is required in Europe(3). The laboratory must analyze a set of 85-100 samples to test their inaccuracy, repeatability & reproducibility for the measurement of
SRL. In addition, three blindness samples need to be
analyzed each month to demonstrate their continued proficiency, including 2 spiked to a known concentration, and
another pooled sample from patients receiving SRL.
Interfering peaks in the chromatograms, requiring
tedious extraction procedures and long run times to resolve
the peaks, complicated most of these assays. A limit of
quantification (LOQ) of 2.5 ng/mL or lower is important as
SRL C0 of most renal transplant recipients has been maintained at 5-15 ng/mL(8).
Most of these methods required a sample volume of
 1 mL, adopted 32- desmethoxy rapamycin as the IS, and
used methanol or methanol water to prepare stock standards
of SRL and the IS (Table 4).
IV. Extraction of SRL from Whole Blood
One of the most common problems associated with
SRL HPLC-UV assays of samples from biologic matrices is
chromatographic interference. Rigorous and technically
demanding extraction procedures are required to remove
proteinaceous and other substances that strongly absorb UV
light at 280 nm, a wavelength close to the relatively weak
UV extinction maximum of SRL (278 nm)(25). The method
reported by French et al.(18) had proteinaceous substances
precipitated by ZnSO4 as those required by HPLC/MS/MS
methods and made the following extraction procedure
easier.
Liquid/liquid extraction is universally used, whereas
solid phase extraction was used by Svensson et al.(12) only.
Only glass tubes should be used in the extraction procedure.
Polypropylene tubes used during the extraction may cause
interferences. Teflon-coated screw caps or phenolic caps
assembled with Teflon liners are also crucial during the

extraction procedure(13,14). Cardboard seals interfere with
chromatography(16). All the methods add alkali or buffer to
samples before extraction with organic solvent (Table 4).
When extraction was performed at high pH (e.g. adding
Na2CO3, or K2CO3), SRL and especially the IS isomerized.
The isomerization occurred to a lesser extent without
addition of alkaline buffer, and was negligible at pH 4.7
(Na acetate buffer)(12). However, our study using method
reported by French et al. revealed that addition of adequate
alkali was crucial during the extraction of SRL before
HPLC-UV assay. For months, the assay outcome was too
unstable to achieve a calibration curve. The assay could be
continued only after increasing the volume of NaOH. As
the most stable range of pH for SRL in aqueous solution is
between pH 4.5 and 6.0, it is safe as long as the pH does
not exceed 6.0-6.5 during this extraction step. With inadequate alkali, the recovery of SRL and the IS may drop dramatically (Figure 2 (A), (B), (C) and (D)).
Most procedures utilized 1-chlorobutane (butyl
chloride) as extraction solvent (Table 4). Svensson et al.(12)
indicated that extraction with 1-chlorobutane gave a clean
extract but low recovery of SRL and the IS. Diethylether
gave higher recovery but dirty extract with too much
residue after evaporation; while a mixture of equal amounts
of 1-chlorobutane and ether gave a higher recovery than
pure 1-chlorobutane and a relatively clean extract. Due to
possible interference from extraction solvent of some
brands, it is important to have extraction solvent tested
before starting the procedure.
As 95% of SRL is partitioned into red blood cells,
vortex or shaking is very important for adequate and
uniform recovery. Extraction time varied in different
methods. By using reciprocal shaker, Svensson et al.(12)
indicated that 30 min of extraction gave higher recovery
than 15 min, whereas 60 min extraction did not give any
further improvement. In our experience, vortex time longer
than 2 min may be required if there is no further shaking.
Temperature used during evaporation of the extract ranged
from room temperature to 60˚C (Table 4). Although SRL is
heat unstable, it is important to keep temperature at 25˚C or
higher during evaporation, especially during winter.
A further purification with reverse-phase solid-phase
extraction may give clear colorless solution if the residue
from the liquid/liquid extraction was not clean enough for
injection on HPLC(12). Back extraction with hexane also
reduced UV interferences(15,16,18).
Because of the light-sensitivity of SRL, early studies
required that all work performed in a darkened fume
hood(13,14). However, such requirement did not appeared in
the latter study(18).
V. HPLC-UV Condition for SRL Assay
The maximal absorbance by SRL at 276 or 278 nm
was used in UV detection. In some HPLC systems, SRL
and the IS exhibit two peaks in the chromatogram(12,18). In
solution these compounds exist as an equilibrium mixture
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of rapidly inter-converting isomers A, B, and C. The major
component of SRL is isomer B, while isomer C accounts
for approximately 3-10% of various SRL formulations.
The amount of isomer A in the formulation is generally <
0.5% (Information from Wyeth-Ayerst).

(A)

DAD1 A, Sig = 278,8 Ref = 360,100 (D:\200301~1\040107\CALIBH01.D)

11.596 - IS B

mAU
1.2
1
0.8
0.6
0.4
0.2
0
-0.2
-0.4
5

7.5

10

2.5

5

7.5

10

5

7.5

15

17.5

min

10

12.5

15

17.5

min

DAD1 A, Sig = 278,8 Ref = 360,100 (D:\200301~1\040309\CALIBA01.D)

11.403 - IS B
10.359

mAU
1.2
1
0.8
0.6
0.4
0.2
0
-0.2
-0.4
0

12.5

11.490 - IS B

9.225 - SRL B

2.5

9.115 - SRL B

(D)

min

DAD1 A, Sig = 278,8 Ref = 360,100 (D:\200301~1\040309\CALIBH01.D)

mAU
1.2
1
0.8
0.6
0.4
0.2
0
-0.2
-0.4
0

17.5

13.094

9.173 - SRL B

(C)

15

DAD1 A, Sig = 278,8 Ref = 360,100 (D:\200301~1\040309\CALIBH01.D)

mAU
1.2
1
0.8
0.6
0.4
0.2
0
-0.2
-0.4
0

12.5

2.5

5

7.5

10

13.077

(B)

2.5

11.408 - IS B

0

12.5

15

17.5

min

Figure 2. Chromatograms of (A) extract of blank whole blood spiked
with 2.5 ng/mL SRL and 32.6 ng/mL IS, and alkalized with 200 µL
of NaOH, (B) extract of blank whole blood spiked with 2.5 ng/mL
SRL and 32.6 ng/mL IS, and alkalized with 300 µL of NaOH, (C)
extract of blank whole blood spiked with 75 ng/mL SRL and 32.6
ng/mL IS, and alkalized with 200 µL of NaOH, and (D) extract of
blank whole blood spiked with 75 ng/mL SRL and 32.6 ng/mL IS,
and alkalized with 300 µL of NaOH.

Mobile phase played a vital role in the HPLC/UV
analysis of SRL. Our preliminary study revealed that
CH3CN 60% in H2O, as that adopted by French et al.(18),
could successfully separate isomer B and isomer C of SRL
and the IS. But the mobile phase MeOH/CH 3CN/H 2O
(68/2/30 in volume as reported by Maleki et al. (16) or
68/12/20 in volume) failed to elute either SRL or the IS
within 1 hr if Inertsil OD3 column was used. After
changing the mobile phase to MeOH/CH3CN/H2O (78/2/20
in volume or 73/2/25 in volume), both SRL and the IS were
eluted before 17 min, but failed to separate isomer B and
isomer C of SRL and the IS. SRL and the IS were not
separated either.
Immunosuppressants that were commonly combined
with SRL, such as tacrolimus and cyclosporine, and the
breakdown product of SRL (e.g., seco-rapamycin), did not
interfere with HPLC-UV assay(12).
Reverse-phase C18 column was adopted by various
methods. A precolumn filter (guard column, column saver)
was often used. The injected volume ranged from 20 µL to
200 µ L. The most frequently used mobile phase was
methanol water, CH3CN water, or mixture of methanol,
CH3CN and water (Table 4).
Peak-height ratio of SRL/IS was used for SRL quantification. Flow rate in different methods ranged from 0.3
mL/min to 1.5 mL/min. Column temperature employed by
different HPLC-UV methods ranged from 40-70˚C. HPLCUV at room temperature at a commonly flow rate resulted
in very broad peaks. Svensson et al.(12) indicated efficacy
can be improved by increasing column temperature to 70˚C,
and decreasing flow rate to 0.3 mL/min. From our experience, a column temperature slightly below the recommended 50˚C resulted in unstable outcomes, especially in LOQ
(Table 5). It is important to keep column covered and away
from windway of air conditioner to maintain consistent
temperature (50˚C). In addition, an autosampler temperature at 4 ± 2˚C is required to maintain the stability of SRL
in reconstituted solution. However, our experience showed
that rising autosampler temperature to 6˚C during winter
may give more consistent results.

Table 5. Influence of column temperature on the outcome (N=10
runs)
Nominal
Measured
Recovery
Intraday
concentration
concentration
(%)
% CV
(ng/mL)
(ng/mL)
2.5
0.0-3.5
0.0-142.9
22.7-141.4%
7.5
4.5 and 9.5
59.9 and 127.2
50.8%
22.5
20.2 and 29.9
89.6 and 132.8
27.5%
58
40.4 and 65.3
69.7 and 112.5%
33.2%
When HPLC was placed under the windway of air conditioner,
measured concentrations at LOQ did not meet the requirement of
intraday % CV less than 20% in 8 out of 10 runs, even when column
oven was covered. On the other hand, only 1 out of 10 did not meet
the requirement of intraday % CV less than 15% at higher concentrations.
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CONCLUSIONS
The HPLC-UV method we used to determine SRL
concentration in human whole blood was validated. SRL
whole blood concentration determined by HPLC-UV had a
LOQ close to the lower limit of therapeutic range. Samples
should be refrigerated and protected from light once
collected. Rigorous and technically demanding extraction
procedures are required. Extraction solvent should be
tested for interference before use. Adequate alkali during
extraction, appropriate temperature during evaporation, and
sufficient column temperature are key factors of the assay.
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